Common misdiagnosis of partial mole is
What is the FDA-recommended time interval between Mifepristone and Misoprostol administration in medical termination of pregnancy?
The best method for inducing mid trimester abortion is :
Which of the following conditions is ruled out in a twin pregnancy of the same age and sex?
Most common antigen involved in erythroblastosis fetalis is:
What would be the type of presentation when the engaging diameter is mentovertical?
Which of the following statements about abdominal pregnancy is true?
A 45-year-old female with a history of G5P4A0L4 has her last menstrual period (LMP) on August 25, 2014. What is the gestational age in weeks on May 11, 2015?
Which of the following precancerous conditions, if treated, has the highest likelihood of not leading to cancer?
In MRKH syndrome, which of the following structures is typically absent?
NEET-PG 2015 - Obstetrics and Gynecology NEET-PG Practice Questions and MCQs
Question 21: Common misdiagnosis of partial mole is
- A. Choriocarcinoma
- B. Complete mole
- C. Ectopic pregnancy
- D. Threatened abortion (Correct Answer)
Explanation: ***Threatened abortion*** - Partial moles often present with **vaginal bleeding** and a uterus size appropriate for gestational age, mimicking the symptoms of a **threatened abortion**. - **Fetal heartbeat** may be detectable in a partial mole, further complicating differentiation from a threatened abortion without detailed ultrasound or histological examination. *Choriocarcinoma* - **Choriocarcinoma** is a malignant tumor and a complication of molar pregnancy, not a common misdiagnosis of an early partial mole. - While both involve abnormal trophoblastic tissue, **choriocarcinoma** follows a molar pregnancy (or other gestations) and presents with systemic symptoms and very high hCG levels, distinct from the initial presentation of a partial mole. *Complete mole* - **Complete moles** are distinct from partial moles both genetically (46,XX or 46,XY with paternal origin only) and pathologically (no fetal tissue, generalized hydropic villi). - While both are types of molar pregnancy, they have different management and prognostic implications, and are distinct entities rather than a misdiagnosis of one for the other's initial presentation. *Ectopic pregnancy* - An **ectopic pregnancy** typically presents with pain and vaginal bleeding, along with an empty uterus on ultrasound. - While both involve abnormal pregnancy presentations, a **partial mole** usually shows some fetal tissue or identifiable placental tissue within the uterine cavity, distinguishing it from an ectopic pregnancy.
Question 22: What is the FDA-recommended time interval between Mifepristone and Misoprostol administration in medical termination of pregnancy?
- A. 96 hours
- B. 48 hours
- C. 24-48 hours (Correct Answer)
- D. 72 hours
Explanation: ***24-48 hours*** - The FDA-approved protocol for medical abortion with mifepristone and misoprostol specifies a **24- to 48-hour interval** between the administration of the two drugs. - This timing ensures optimal efficacy as it allows mifepristone to adequately sensitize the uterus to the effects of misoprostol. *48 hours* - While 48 hours falls within the recommended range, specifically stating "48 hours" as the only option is less precise than the **24-48 hour window**. - No specific clinical advantage or disadvantage is generally reported for waiting exactly 48 hours over, for instance, 24 hours. *96 hours* - A 96-hour interval is significantly longer than the **FDA-recommended window** and is not part of the standard, evidence-based protocol. - Delaying misoprostol administration beyond 48 hours may **reduce the effectiveness** of the medical abortion and increase the risk of complications. *72 hours* - A 72-hour interval exceeds the upper limit of the **FDA-recommended window** for optimal efficacy. - While some studies have explored extended intervals, the *standard clinical practice* and FDA guidelines do not endorse 72 hours as the primary recommended interval.
Question 23: The best method for inducing mid trimester abortion is :
- A. Dilation and Curettage (D&C)
- B. Injection of Hypertonic Saline
- C. Ethacrydine Lactate
- D. Prostaglandins (Correct Answer)
Explanation: ***Prostaglandins*** - **Prostaglandins** (e.g., dinoprostone, misoprostol) are highly effective in inducing uterine contractions and cervical ripening, making them the preferred method for **mid-trimester abortion**. - They can be administered through various routes (vaginal, oral, buccal) and offer a good balance of efficacy and safety for this gestational age. - Prostaglandins are considered the **current gold standard** for second-trimester medical termination of pregnancy. *Injection of Hypertonic Saline* - Historically used, but **intra-amniotic hypertonic saline** carries significant risks, including hypernatremia, disseminated intravascular coagulation (DIC), and uterine rupture. - It has largely been replaced by safer and more effective methods like prostaglandins due to its adverse event profile. - This method is now considered obsolete in most clinical settings. *Ethacrydine Lactate* - **Ethacrydine lactate** (ethacridine lactate/Rivanol) is an antiseptic agent that was historically used for mid-trimester abortion via intra-amniotic injection. - While it was effective in inducing abortion, it has been largely abandoned due to complications, prolonged induction time, and the availability of safer alternatives. - It is **not the preferred method** compared to prostaglandins, which have better safety profiles and efficacy. *Dilation and Curettage (D&C)* - **Dilation and curettage (D&C)** is primarily used for first-trimester abortions or for managing incomplete abortions and miscarriages. - In the mid-trimester, the uterus is larger and the fetal tissue is more substantial, making D&C less safe and often requiring extensive dilation or potentially leading to complications like uterine perforation or hemorrhage. - **Dilation and evacuation (D&E)** may be used in mid-trimester but requires specialized training and equipment.
Question 24: Which of the following conditions is ruled out in a twin pregnancy of the same age and sex?
- A. Monozygotic twins
- B. Superfetation (Correct Answer)
- C. Superfecundation
- D. None of the following
Explanation: ***Superfetation*** - **Superfetation** refers to the fertilization of an ovum when another pregnancy is already established in the uterus, resulting in two fetuses of **different gestational ages**. - As the question specifies a twin pregnancy of the **same age**, superfetation is ruled out. *Monozygotic twins* - **Monozygotic twins** originate from a single zygote that splits, resulting in genetically identical individuals of the **same sex** and age. - This condition is consistent with the given scenario of same-sex, same-aged twins. *Superfecundation* - **Superfecundation** is the fertilization of two or more ova from the same ovulatory cycle by sperm from **different acts of coitus** (which may involve different partners). - The twins are of the **same gestational age** (same cycle) but are **dizygotic**, and can be either the same sex or different sexes. - This condition is NOT ruled out by the criteria given in the question. *None of the following* - This option is incorrect because **superfetation** is definitively ruled out by the criteria of the question (twins of the same age).
Question 25: Most common antigen involved in erythroblastosis fetalis is:
- A. C antigen in Rh group
- B. E antigen in Rh group
- C. Duffy antigen
- D. D antigen in Rh group (Correct Answer)
Explanation: ***D antigen in Rh group*** - The **D antigen** is the most immunogenic of the Rh antigens and is responsible for the vast majority of cases of **erythroblastosis fetalis** (hemolytic disease of the fetus and newborn). - When an **Rh-negative mother** is exposed to Rh-positive fetal blood (usually during previous pregnancies or transfusions), she can form antibodies against the D antigen, which can then cross the placenta in subsequent pregnancies and attack Rh-positive fetal red blood cells. *C antigen in Rh group* - While the **C antigen** is part of the Rh blood group system, antibodies to it are much less common and typically cause less severe hemolytic disease compared to anti-D antibodies. - The C antigen is less immunogenic than the D antigen, meaning it is less likely to provoke an immune response in an Rh-negative individual. *E antigen in Rh group* - Similar to the C antigen, the **E antigen** is another Rh antigen, but antibodies against it (anti-E) are also less frequently implicated in severe erythroblastosis fetalis than anti-D. - Antibodies to E can cause hemolytic disease, but their clinical significance is usually milder than that of anti-D. *Duffy antigen* - The **Duffy antigen system** is separate from the Rh system and is known for its role in resistance to certain malarial parasites (e.g., *Plasmodium vivax*). - Although antibodies to Duffy antigens (anti-Fya, anti-Fyb) can cause **hemolytic disease of the fetus/newborn**, they are a far less common cause of erythroblastosis fetalis than antibodies to the Rh D antigen.
Question 26: What would be the type of presentation when the engaging diameter is mentovertical?
- A. Face
- B. Vertex
- C. Brow (Correct Answer)
- D. Breech
Explanation: ***Brow*** - The **mentovertical diameter** (13.5 cm) is the engaging diameter in **brow presentation**. - This diameter extends from the **chin (mentum) to the vertex** of the fetal head. - Brow presentation occurs when the fetal head is **partially deflexed**, presenting the area between the orbital ridge and the anterior fontanelle. - This is the **largest anteroposterior diameter** of the fetal head and makes vaginal delivery extremely difficult or impossible. *Face* - In **face presentation**, the fetal head is **completely hyperextended**, and the engaging diameter is **submentobregmatic** (9.5 cm), not mentovertical. - This diameter extends from below the chin to the bregma. - Face presentation can allow vaginal delivery if the mentum is anterior. *Vertex* - **Vertex presentation** is the most common and favorable presentation, with the fetal head fully flexed. - The engaging diameter is **suboccipitobregmatic** (9.5 cm), from the subocciput to the bregma. - The occiput presents first in this presentation. *Breech* - **Breech presentation** involves the fetal buttocks or feet presenting first. - The engaging diameter is **bitrochanteric** (transverse diameter), not related to cephalic diameters like mentovertical.
Question 27: Which of the following statements about abdominal pregnancy is true?
- A. Primary abdominal pregnancy is a common condition.
- B. Most fetuses in abdominal pregnancies survive to term.
- C. Leaving the placenta behind can lead to infection. (Correct Answer)
- D. Separation of the placenta is always necessary.
Explanation: ***f6629bc8-61b2-4393-bb4c-9c32cd943e34*** - **Placenta acreta-like implantation** of the placenta into intra-abdominal organs or the abdominal wall makes removal dangerous due to potential damage and massive hemorrhage. - While leaving it in place can lead to serious complications like **infection**, **abscess formation**, or **secondary hemorrhage** as it degenerates, the risks of immediate removal often outweigh these, necessitating careful observation and management. *020c0067-d7b2-4fc2-85ae-2d6ba40ab437* - **Primary abdominal pregnancy** is extremely rare, accounting for less than 1% of all extrauterine pregnancies. - Abdominal pregnancies are generally **secondary** due to tubal abortion or rupture with subsequent reimplantation. *3560b92d-a63d-4966-8872-e4f56a82882f* - **Fetal survival rates** in abdominal pregnancies are very low, with a high incidence of **fetal anomalies** and **perinatal mortality**. - The abnormal placental implantation and lack of amniotic fluid protection lead to significant **growth restriction** and compression deformities. *5ab987e0-68ca-43f2-a8f2-238a5eb0c4f8* - The decision to remove the **placenta** in an abdominal pregnancy is complex and depends on its implantation site; often, it is left in situ due to the high risk of **hemorrhage** from attempting removal. - Removing the placenta can cause **uncontrollable bleeding**, especially if it is attached to vital organs or large blood vessels.
Question 28: A 45-year-old female with a history of G5P4A0L4 has her last menstrual period (LMP) on August 25, 2014. What is the gestational age in weeks on May 11, 2015?
- A. 37 weeks (Correct Answer)
- B. 32 weeks
- C. 35 weeks
- D. 40 weeks
Explanation: ***37 weeks*** - Calculating from **LMP (August 25, 2014)** to assessment date **(May 11, 2015)**: Days remaining in August: 6 days (26th-31st), September through April: 242 days, Days in May: 11 days. - **Total: 259 days ÷ 7 = exactly 37 weeks** gestational age using standard **Naegele's rule** calculation method. *32 weeks* - This option would correspond to an assessment date in early April 2015, which is **too early** given the LMP and assessment date. - It suggests a **5-week shorter** pregnancy duration than the actual interval calculated. *35 weeks* - This option indicates an assessment around the third week of April 2015, which is still **earlier** than the May 11, 2015, date. - It implies a **2-week shorter** gestational period than the correct calculation shows. *40 weeks* - This option would correspond to an assessment date in early June 2015, **beyond** the May 11, 2015, assessment date. - This gestational age is **too long** for the specified dates and would suggest the patient is at **term** or past her due date.
Question 29: Which of the following precancerous conditions, if treated, has the highest likelihood of not leading to cancer?
- A. Cervical intraepithelial Neoplasia (Correct Answer)
- B. Ductal carcinoma in situ of breast
- C. Lobular carcinoma in situ of breast
- D. Vaginal intraepithelial neoplasia
Explanation: ***Cervical intraepithelial neoplasia (CIN)*** - CIN has a high success rate with treatment (e.g., **cryotherapy**, **LEEP**), often completely eradicating the dysplastic cells and preventing progression to **invasive cervical cancer**. - The effectiveness of screening via **Pap smears** allows for early detection and intervention, significantly reducing cancer risk. *Ductal carcinoma in situ (DCIS) of breast* - While treatable, DCIS carries a higher risk of recurrence and progression to **invasive breast cancer** in the same or contralateral breast compared to CIN. - Treatment often involves **lumpectomy** with or without radiation, and sometimes **total mastectomy**, reflecting its more serious potential. *Lobular carcinoma in situ (LCIS) of breast* - LCIS is largely considered a **risk indicator** for future invasive cancer in either breast, rather than a direct precursor that inevitably progresses. - Management often involves **close surveillance** or **chemoprevention**, as surgical excision does not prevent cancer development in other areas of the breast. *Vaginal intraepithelial neoplasia (VAIN)* - While treatable, VAIN is less common and often coexists with or follows **cervical or vulvar neoplasia**, indicating a broader field defect due to **HPV**. - Recurrence rates post-treatment can be significant, and patients often require long-term follow-up due to the continued risk of progression.
Question 30: In MRKH syndrome, which of the following structures is typically absent?
- A. Testes
- B. Uterus (Correct Answer)
- C. Breast development
- D. Pubic hair development
Explanation: ***Uterus*** - **Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome** is characterized by congenital aplasia of the **uterus** and upper two-thirds of the vagina. - This is due to abnormal development of the **Müllerian ducts**, which are embryonic structures that form the uterus, fallopian tubes, cervix, and upper vagina. *Breast development* - **Breast development** is typically normal in MRKH syndrome as it is influenced by ovarian hormones, and the **ovaries are usually functional** in these individuals. - Normal breast development indicates that the **estrogen production** from the ovaries is intact. *Pubic hair development* - **Pubic hair development** is also normal in MRKH syndrome, as it is a secondary sexual characteristic driven by **adrenal androgens** and ovarian hormones, which are generally not affected. - The presence of pubic hair indicates **normal adrenal and ovarian androgen production**. *Testes* - **Testes** are male gonads and are therefore not present in individuals with MRKH syndrome, as these patients are **genetically female (46,XX karyotype)**. - The absence of testes is a normal finding in females, and thus not a characteristic feature or absence due to MRKH syndrome itself.